Art

J-GLOBAL ID：201902275815089708   Reference number：19A0666509

卵巣癌・子宮頸癌のBevacizumabの実際

Author (1)： SUMI TOSHIYUKI (大阪市大 大学院医学研究科 女性病態医学)
Material： 東海産科婦人科学会雑誌  (Tokai Journal of Obstetrics and Gynecology)
Volume： 55  Page： 31-35  Publication year： Mar. 09, 2019 
JST Material Number： L2634A  ISSN： 0915-7204  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human ,...
Semi thesaurus term： cisplatin ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0666509&from=J-GLOBAL&jstjournalNo=L2634A") }}

JST classification (3)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Tumors(=neoplasms)of female genitalia and fetus  (GS04000K) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (2)： Paclitaxel ,  CPT-11

Reference (10)：

• Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21: 3194-3200.
• Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96: 1682-1691.
• Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009; 374: 1331-1338.
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365: 2473-2483.
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365: 2484-2496.

Terms in the title (3)： 卵巣癌 ,  子宮頸癌 ,  BEVACIZUMAB